Research on acute myeloid leukemia has led to the identification of various signatures and biomarkers that may predict patient prognosis and therapeutic response. These include signatures related to cell death patterns, unfolded protein responses, and immune cell interactions. The specific mechanisms and markers involved are still being explored, with different studies highlighting distinct potential predictors of patient outcomes.